Budison F-200 Arocap Dry Powde

Budesonide: This is an anti-inflammatory corticosteroid with strong glucocorticoid activity and only weak mineralocorticoid activity. Inflammation plays a major role in how asthma develops. Corticosteroids act broadly to inhibit many of the cell types (such as mast cells, eosinophils, neutrophils, macrophages and lymphocytes) and mediators (such as histamine, eicosanoids, leukotrienes and cytokines) that drive both allergic and non-allergic inflammation. These anti-inflammatory effects are thought to contribute to the drug's benefit in asthma.

Formoterol Fumarate Dihydrate: This is a long-acting, selective beta2-adrenergic agonist that starts working quickly. When inhaled, Formoterol Fumarate Dihydrate BP acts directly in the lungs as a bronchodilator. Like other beta2-adrenoceptor agonists, its effects come from stimulating intracellular adenyl cyclase, the enzyme that converts adenosine triphosphate (ATP) into cyclic AMP. The resulting rise in cyclic AMP relaxes the smooth muscle of the airways and reduces the release of mediators of immediate hypersensitivity from cells, particularly from mast cells.

For this combination, or for the concomitant treatment with Formoterol and Budesonide, no clinical data on exposed pregnancies are available. Data from an embryo-foetal development study in the rat showed no evidence of any additional effect from the combination there. There are no adequate data on the use of Formoterol in pregnant women. In animal studies, Formoterol has caused adverse effects in reproduction studies, but only at very high systemic exposure levels. Budesonide is excreted in breast milk; however, at therapeutic doses, no effects on the suckling child are anticipated. It is not known whether Formoterol passes into human breast milk, though in rats, small amounts of Formoterol have been detected in maternal milk. This combination should be given to breast-feeding women only if the expected benefit to the mother is greater than any possible risk to the child.

If a child is on inhaled corticosteroids for a long time, their height should be checked regularly. This applies to Budesonide + Formoterol Fumarate too. When growth slows, the treatment should be looked at again, with the aim of lowering the dose of the inhaled corticosteroid. The doctor must weigh the benefits of the corticosteroid against the possible risk of stunted growth. Referral to a paediatric respiratory specialist should also be considered.

An overdose of formoterol would most likely cause the effects typical of (32 adrenoceptor agonists: tremor, headache and palpitations. Isolated cases have also reported tachycardia, hyperglycaemia, hypokalaemia, a prolonged QTc-interval, arrhythmia, nausea and vomiting. Supportive and symptomatic treatment may be needed. A dose of 90 micrograms given over three hours to patients with acute bronchial obstruction raised no safety concerns.

Acute overdosage with budesonide, even in excessive doses, is not expected to be a clinical problem. If it is used chronically in excessive doses, systemic glucocorticosteroid effects such as hypercorticism and adrenal suppression may appear.

Budesonide + Formoterol Fumarate inhalation capsules must not be swallowed. Use them only with the inhalation device. Keep them away from light and from damp places, and store them at or below 25°C. Keep the capsules out of reach of children. Take a capsule out of the blister pack only just before you put it in the inhalation device, because a capsule that has been exposed to moisture may not be pierced easily.